期刊文献+

基于“肺通调水道”理论探究CFTR介导下鞘脂代谢失衡对慢性阻塞性肺疾病的调控机制

Based on the Theory of“ Lung Channel Regulation”, the Regulatory Mechanism of CFTR-MediatedImbalance of Infingolipid Metabolism on Chronic Obstructive Pulmonary Disease was Investigated
下载PDF
导出
摘要 目的探讨CFTR调控下鞘脂代谢在COPD中的发病过程及作用途径,进一步阐释肺通调水道理论。方法烟熏法建立COPD小鼠模型,同时烟熏加CFTR激动剂建立CFTR模型,观察肺组织病理变化评估小鼠模型,采用LC-MS质谱检测模型血浆中鞘脂代谢产物Ceramide及sphingosine-1-phosphate表达,采用Western blot方法检测小鼠模型肺组织中Sphks、ASM、CFTR蛋白磷酸化水平,采用荧光定量PCR小鼠模型肺组织中Sphks、Smpd基因(ASM)、CFTRmRNA转录水平。结果COPD组、CFTR干预组中S1p表达均较对照组降低(P<0.05),CFTR干预组较COPD组表达高(P<0.05);CFTR、Sphk1蛋白磷酸化水平在COPD组及CFTR干预组均呈低表达,COPD组表达最低与对照组、CFTR干预组有差异(P<0.05),Sphk2在COPD组与对照组存在差异(P<0.05)。ASM在COPD组、CFTR干预组高于对照组(P<0.05)。CFTR mRNA在COPD组及CFTR干预组均较对照组低,COPD组与对照组存在差异(P<0.05),Sphk1 mRNA在对照组表达最高,且与COPD组、CFTR干预组均存在差异(P<0.05),SMPD1 mRNA在COPD组及CFTR干预组呈高表达,且与对照组有差异(P<0.05)。结论探讨肺通调水道功能失司在COPD疾病中的物质变化基础,揭示CFTR通过参与调控鞘脂代谢,从而影响COPD水液代谢的途径。 Objective The material basis and pathway of CFTR regulation of sphingolipid metabolism in COPD were discussed,and the theory of lung channel regulation was further elucidated.Methods The mouse model of COPD was established by smoking method,and the CFTR model was established by smoking plus CFTR agonist.The pathological changes of lung tissues were observed and the mouse model was evaluated.Ceramide and sphingosine-1-phosphate expression of sphingolipid metabolites in plasma of the model were detected by LC-MS mass spectrometry.Western blot was used to detect the phosphorylation levels of Sphks,ASM and CFTR proteins in the lung tissue of the mouse model.Quantitative fluorescence PCR was used to detect the mrna transcription levels of Sphks,Smpd and CFTR mRNA in the lung tissue of the mouse model.Results The expression of S1p in COPD group and CFTR intervention group was lower than that in control group(P<0.05),and the expression of S1P in CFTR intervention group was higher than that in COPD group(P<0.05).The protein phosphorylation levels of CFTR and Sphk1 were low in COPD group and CFTR intervention group,the lowest expression in COPD group was different from that in control group and CFTR intervention group(P<0.05),and Sphk2 was different in COPD group and control group(P<0.05).ASM in COPD group and CFTR intervention group was higher than that in control group(P<0.05).CFTR mRNA in COPD group and CFTR intervention group was lower than that in control group,and there were differences between COPD group and control group(P<0.05).Sphk1 mRNA expression was the highest in control group,and there were differences between it and COPD group and CFTR intervention group(P<0.05).SMPD1 mRNA was highly expressed in COPD group and CFTR intervention group,and was different from control group(P<0.05).Conclusion To explore the material changes of pulmonary aqueduct dysfunction in COPD diseases,and to reveal the pathway of CFTR affecting water and fluid metabolism in COPD by participating in the regulation of sphingolipid metabolism.
作者 徐丹 崔萌萌 郭辉 李争 王晶 荆晶 李风森 王欣 XU Dan;CUI Mengmeng;GUO Hui;LI Zheng;WANG Jing;JING Jing;LI Fengsen;WANG Xin(The Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University,Urumqi 830000,China;Xinjiang Key Laboratory of Respiratory Diseases,Urumqi 830000,China;The Fourth Clinical Medical College of Xinjiang Medical University,Urumqi 830000,China)
出处 《世界科学技术-中医药现代化》 CSCD 北大核心 2024年第7期1931-1938,共8页 Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金 新疆维吾尔自治区卫生健康青年医学科技人才专项(WJWY-202227):基于“肺通调水道”理论研究CFTR调控下鞘脂代谢失衡对慢阻肺水液代谢的影响,负责人:徐丹。
关键词 慢性阻塞性肺疾病 CFTR 鞘脂 肺通调水道 Chronic obstructive pulmonary disease CFTR Sphingolipid Lung regulates the water channel
  • 相关文献

参考文献9

二级参考文献49

  • 1黄继汉,黄晓晖,陈志扬,郑青山,孙瑞元.药理试验中动物间和动物与人体间的等效剂量换算[J].中国临床药理学与治疗学,2004,9(9):1069-1072. 被引量:1357
  • 2GoSi FM, Alonso A. Sphingomyelinases: enzy- mology and membrane activity [J]. FEBS Lett, 2002, 531 (1) :38-46.
  • 3Teichgrber V, Ulrich M, Endlich N, Riethm011er J, Wilker B, De Oliveira-Munding CC, et aL Ce- ramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis [J]. Nat Med, 2008, 14(4) :382-391.
  • 4Becker KA, Riethmller J, Lth A, D6ring G, Kle- user B, Gulbins E. Acid sphingomyelinase inhibi- tors normalize pulmonary ceramide and inflamma- tion in cystic fibrosis[J]. Am J Respir Cell Mol Biol, 2010, 42(6) .716-724.
  • 5He X, Chen F, Dagan A, Gatt S, Schuchman EH. A fluorescence-based, high-performance liquid chromatographic assay to determine acid sphingomyelinase activity and diagnose types A and B Niemann-Pick disease [ J ]. Anal Biochem, 2003, 314(1 ) :116-120.
  • 6Coker RK, Laurent GJ. Pulmonary fibrosis: cyto- kines in the balance [ J ]. Eur Respir J, 1998, 11 (6) :1218-1221.
  • 7Richmond JM, Duffy ER, Lee J, Kaboli K, Kim YS, Remick DG, et al. Mannose-capped Lipoara- binomannan from Mycobacterium tuberculosis induces soluble tumor necrosis factor receptor pro- duction through tumor necrosis factor alpha-con- verting enzyme activation [ J ]. Infect Immun, 2012, 80( 11 ) :3858-3868.
  • 8Perkins RC, Scheule RK, Hamilton R, Gomes G, Freidman G, Holian A. Human alveolar macro- phage cytokine release in response to in vitro andin vivo asbestos exposure[J]. Exp Lung Res, 1993, 19(1 ) .55-65.
  • 9Lapp NL, Castranova V. How silicosis and coal workers' pneumoconiosis develop -a cellular assessment[J]. Occup Med, 1993, 8(1 ) :35-56.
  • 10Becker KA, Riethm:ller J, Zhang Y, Gulbins E. The role of sphingolipids and ceramide in pulmona- ry inflammation in cystic fibrosis [J] Open Respir Med J, 2010, 4 :39-47.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部